The Rapid Opioid Dependence Screen (RODS) is an 8-item measure of opioid dependence designed for quick, targeted screening in clinical and research settings. Based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, criteria, the RODS has an average administration of less than 2 minutes and can easily be administered as a stand-alone instrument or as part of a comprehensive interview. This study reports on the initial validation of the RODS among a sample of 97 newly incarcerated, HIV-positive individuals. Using the Mini International Neuropsychiatric Interview as the primary measure of opioid dependence, the RODS showed good-to-strong sensitivity (.97), specificity (.76), positive predictive value (.69), and negative predictive value (.98), while concordance analysis revealed moderate diagnostic agreement (κ = .67). Psychometric properties revealed strong internal consistency (α = .92) and inter-item correlations (.66 to .87).
AlistarS. S., OwensD. K., BrandeauM. L. (2011). Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: A modeling analysis for Ukraine. PLoS Medicine, 8, e1000423. doi:10.1371/journal.pmed.1000423
2.
AlticeF. L., BruceR. D., LucasG. M., LumP. J., KorthuisP. T., FlaniganT. P., … BHIVES Collaborative. (2011). HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: Results from a multisite study. Journal of Acquired Immune Deficiency Syndromes, 56, S22–S32. doi:10.1097/QAI.0b013e318209751e
3.
AlticeF. L., KamarulzamanA., SorianoV. V., SchechterM., FriedlandG. H. (2010). Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet, 376, 59–79. doi:10.1016/S0140-6736(10)60829-X
4.
AlticeF. L., SullivanL. E., Smith-RohrbergD., BasuS., StancliffS., EldredL. (2006). The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clinical Infectious Diseases, 43, S178–S183. doi:CID40075 [pii] 10.1086/508181
5.
BasuS., Smith-RohrbergD., BruceR. D., AlticeF. L. (2006). Models for integrating buprenorphine therapy into the primary HIV care setting. Clinical Infectious Diseases, 42, 716–721. doi:10.1086/500200
6.
BlackD. W., ArndtS., HaleN., RogersonR. (2004). Use of the Mini International Neuropsychiatric Interview (MINI) as a screening tool in prisons: Results of a preliminary study. Journal of the American Academy of Psychiatry and the Law, 32, 158–162.
7.
BradleyC. J., FrenchM. T., RachalJ. V. (1994). Financing and cost of standard and enhanced methadone treatment. Journal of Substance Abuse Treatment, 28, 155–173.
ChatterjiS., SaundersJ. B., VrastiR., GrantB. F., HasinD., MagerD. (1997). Reliability of the alcohol and drug modules of the Alcohol Use Disorder and Associated Disabilities Interview Schedule—Alcohol/Drug Revised (AUDADIS-ADR): An international comparison. Drug and Alcohol Dependence, 47, 171–185. doi:10.1016/s0376-8716(97)00088-4
10.
CottlerL. B., RobinsL. N., HelzerJ. E. (1989). The reliability of the CIDI-SAM: A comprehensive substance abuse interview. British Journal of Addiction, 84, 801–814. doi:10.1111/j.1360-0443.1989.tb03060.x
11.
DraineJ., AhujaD., AlticeF. L., ArriolaK. J., AveryA. K., BeckwithC. G.…TinsleyM. J. (2011). Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care, 23, 366–377. doi:10.1080/09540121.2010.507738
12.
DunlapL. J., FrenchM. T. (1998). A comparison of two methods for estimating the costs of substance abuse treatment. Journal of Maintenance in the Addictions, 1, 29–44.
13.
FrenchM. T., BradleyC. J., CalingaertB., DennisM. L., KaruntzosG. T. (1994). Cost analysis of training and employment services in methadone treatment. Evaluation and Program Planning, 17, 107–120.
14.
FrenchM. T., GalinisD. N., DunlapL. J., ZarkinG. A., RachalJ. V. (1994). The impact of health care reform and managed care on the availability, financing, and costs of substance abuse treatment. Research Triangle Park, NC: National Institute on Drug Abuse.
15.
GersteinD. R., JohnsonR. A., HarwoodH. J., FountainD., SuterN., MalloyK. (1994). Evaluating recovery services: The California Drug and Alcohol Treatment Assessment (CALDATA). Sacramento, CA: California Department of Alcohol and Drug Programs.
16.
GorsuchR. L. (1997). Exploratory factor analysis: Its role in item analysis. Journal of Personality Assessment, 68, 532–560. doi:10.1207/s15327752jpa6803_5
17.
GossopM., DarkeS., GriffithsP., HandoJ., PowisB., HallW., StrangJ. (1995). The Severity of Dependence Scale (SDS): Psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction, 90, 607–614. doi:10.1046/j.1360-0443.1995.9056072.x
18.
GrantB. F., DawsonD. A., StinsonF. S., ChouP. S., KayW., PickeringR. (2003). The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): Reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. Drug and Alcohol Dependence, 71, 7–16. doi:10.1016/s0376-8716(03)00070-x
19.
GrantB. F., HarfordT. C., DawsonD. A., ChouP. S., PickeringR. P. (1995). The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): Reliability of alcohol and drug modules in a general population sample. Drug and Alcohol Dependence, 39, 37–44. doi:10.1016/0376-8716(95)01134-k
20.
GuadagnoliE., VelicerW. F. (1988). Relation of sample size to the stability of component patterns. Psychological Bulletin, 103, 265–275.
21.
GunterT. D., ArndtS., WenmanG., AllenJ., LovelessP., SieleniB., BlackD. W. (2008). Frequency of mental and addictive disorders among 320 men and women entering the Iowa prison system: Use of the MINI-Plus. Journal of the American Academy of Psychiatry and the Law, 36, 27–34.
22.
JonesJ. E. (2005). Clinical assessment of Axis I psychiatric morbidity in chronic epilepsy: A multicenter investigation. Journal of Neuropsychiatry and Clinical Neuroscience, 17, 172–179.
23.
KrupitskyE., NunesE. V., LingW., IlleperumaA., GastfriendD. R., SilvermanB. L. (2011). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. Lancet, 377, 1506–1513. doi:10.1016/S0140-6736(11)60358-9
24.
LecrubierY., SheehanD. V., WeillerE. (1997). The Mini International Neuropsychiatric Interview: Reliability and validity according to the CIDI. European Psychiatry, 12, 224–231.
25.
MathersB., DegenhardtL., PhillipsB., WiessingL., HickmanM., StrathdeeS.…MattickR. (2008). Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet, 372, 1733–1745.
26.
MattickR. P., BreenC., KimberJ., DavoliM. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, CD002209. doi:10.1002/14651858.CD002209.pub2
27.
MaxwellJ. C. (2011). The prescription drug epidemic in the United States: A perfect storm. Drug and Alcohol Review, 30, 264–270. doi:10.1111/j.1465-3362.2011.00291.x
28.
McLellanA. T., LuborskyL., WoodyG. E., O’BrienC. P. (1980). An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis, 168(1), 26–33.
29.
New York State Office of Alcoholism and Substance Abuse Services. (2005). Screening for co-occurring disorders using the Modified MINI Screen (MMS): Provider Implementation Plan. Albany, NY: Author.
30.
PetersR. H., GreenbaumP. E., EdensJ. F., CarterC. R., OrtizM. M. (1998). Prevalence of DSM-IV substance abuse and dependence disorders among prison inmates. American Journal of Drug and Alcohol Abuse, 24, 573–587.
31.
PinnintiN. R., MadisonH., MusserE., RissmillerD. (2003). MINI International Neuropsychiatric Schedule: Clinical utility and patient acceptance. European Psychiatry, 18, 361–364.
32.
RaistrickD., BradshawJ., ToberG., WeinerJ., AllisonJ., HealeyC. (1994). Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction, 89(5), 563–572. doi: 10.1111/j.1360-0443.1994.tb03332.x
33.
RobinsL. N., WingJ., WittchenH. U., HelzerJ. E., BaborT. F., BurkeJ.…TowleL. (1988). The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Archives of General Psychiatry, 45, 1069–1077.
34.
RydellC. P., EveringhamS. S. (1994). Controlling cocaine: Supply versus demand programs. Washington, DC: Office of National Drug control Policy, United States Army.
35.
Saber-TehraniA. S., SpringerS. A., QiuJ., HermeM., WickershamJ., AlticeF. L. (2012). Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community: A potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials, 33, 436–444.
36.
SametS., WaxmanR., HatzenbuehlerM., HasinD. S. (2007). Assessing addiction: Concepts and instruments. Addiction Science and Clinical Practice, 4, 19–31.
37.
SheehanD. V., LecrubierY., SheehanK. H., AmorimP., JanavsJ., WeillerE.…DunbarG. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59, 22–33.
38.
SkinnerH. A. (1982). The drug abuse screening test. Addict Behav,, 7(4), 363–371.
39.
Smith-RohrbergD., BruceR. D., AlticeF. L. (2004). Review of corrections-based therapy for opiate-dependent patients: Implications for buprenorphine treatment among correctional populations [Review]. Journal of Drug Issues, 34, 451–480.
40.
SpitzerR. L., WilliamsJ. B. W., GibbonM., FirstM. B. (1990). Structured clinical interview for DSM-III-R. Washington, DC: American Psychiatric Association.
41.
SpitzerR. L., WilliamsJ. B. W., GibbonM., FirstM. B. (1992). The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description.Arch Gen Psychiatry, 49(8), 624–629.
42.
Substance Abuse and Mental Health Services Administration. (2008). National survey on drug use and health (NSDUH): 2008 highlights. Rockville, MD: Author.
43.
Substance Abuse and Mental Health Services Administration. (2009a). National survey on drug use and health: Trends in nonmedical use of prescription pain relievers: 2002 to 2007. Rockville, MD: Author.
44.
Substance Abuse and Mental Health Services Administration. (2009b). Results from the 2008 national survey on drug use and health: National findings. Rockville, MD: Author.
45.
SutherlandG., EdwardsG., TaylorC., PhillipsG., GossopM., BradyR. (1986). The measurement of opiate dependence. British Journal of Addiction, 81(4), 485–494.
46.
United Nations Office on Drugs and Crime. (2010). World drug report 2010. New York, NY: United Nations Publication.
47.
United Nations Office on Drugs and Crime & World Health Organization. (2008). Principles of drug dependence treatment: Discussion paper. Vienna, Austria: World Health Organization.
48.
WickershamJ. A., AzarM. M., CannonC. M., AlticeL. F., SpringerS. A. (2015). Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS). Journal of Correctional Health Care, Advance online publication. doi: 10.1177/1078345814557513
49.
WingJ. K., BaborT., BrughaT., BurkeJ., CooperJ. E., GielR.…SartoriusN. (1990). SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry, 47, 589–593.
50.
WolfeD., CarrieriM. P., ShepardD. (2010). Treatment and care for injecting drug users with HIV infection: A review of barriers and ways forward. Lancet, 376, 355–366. doi:10.1016/S0140-6736(10)60832-X
51.
WolfeD., CohenJ. (2010). Human rights and HIV prevention, treatment, and care for people who inject drugs: Key principles and research needs. Journal of Acquired Immune Deficiency Syndromes, 55, S56–S62. doi:10.1097/QAI.0b013e3181f9c0de 00126334-201012011-00011 [pii]
52.
World Health Organization. (2005). Model list of essential medicines (14th ed.). Geneva, Switzerland: Author.
53.
World Health Organization. (2009). Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: Author.
54.
YudkoE., LozhkinaO., FoutsA. (2007). A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat, 32(2), 189–198. doi: 10.1016/j.jsat.2006.08.002
